TJ-C64B

N/A

Report date: 2026/03/26 20:00:17

Base Information

Drug NameTJ-C64B
Drug Alias NameTJ-C64B
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionTumor necrosis factor receptor superfamily member 9 agonistsAnti-CLDN6
TargetsTumor necrosis factor receptor superfamily member 9Claudin 6
Therapy Area/IndicationsOvarian NeoplasmsStomach Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPreclinical
Originator CompaniesI-Mab Biopharma Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesI-Mab Biopharma Co Ltd
Inactive CompaniesN/A
Active IndicationsOvarian NeoplasmsStomach Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A